Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation



Status:Active, not recruiting
Conditions:Ovarian Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:35 - 50
Updated:4/29/2018
Start Date:June 2015
End Date:June 2019

Use our guide to learn which trials are right for you!

Combination-type oral contraceptives (COCs) have been shown to significantly reduce the risk
of invasive epithelial ovarian cancer (IEOC); this protective effect may be achieved to a
large extent through COCs ability to reduce cell proliferation in the fallopian tube fimbriae
(FTF). The progestin-releasing Mirena® intra-uterine device (IUD) is an increasingly popular
method of contraception, but it is not known if its use will reduce a woman's risk of IEOC.
Mirena® use does not block ovulation in most women but it may release sufficient progestin to
also reduce cell proliferation in the FTF. This study aims to evaluate the effects of the
Mirena® IUD on cell proliferation in the FTF as a possible biomarker of protection against
IEOC.


Inclusion Criteria:

- Women between 35 and 50 years of age (inclusive)

- Women who will be scheduled to undergo an RRSO or RRs

- Women who will have at least one fallopian tube removed for risk-reducing reasons
(with or without removal of ovar(ies))

- Women who are willing to have a Mirena® IUD inserted at least prior to risk-reducing
surgery or who already have the Mirena® in place

- Women using non-hormonal forms of contraception (Note: If a copper IUD is being used,
the IUD must be removed prior to or at time of Mirena insertion.)

Exclusion Criteria:

- Any medical contraindication to use of a Mirena® IUD, including:

- Pregnancy (a pregnancy test is required prior to study entry)

- Known uterine anomaly that distorts the shape of the uterine cavity

- Acute pelvic inflammatory disease

- Postpartum endometritis or endometrial infection

- Known or suspected uterine or cervical neoplasia

- Known history or suspected breast cancer or other progestin-sensitive cancer

- Uterine bleeding of unknown etiology.

- Untreated acute cervicitis, vaginitis, or other lower genital tract infections

- Acute liver disease or liver tumor (benign or malignant)

- Use of tamoxifen, raloxifene, or chemotherapy within the previous 6 months

- Positive pregnancy test

- Breastfeeding

- Use of a copper IUD if the patient is not willing to have it removed prior to surgery
and replaced with a Mirena® IUD
We found this trial at
6
sites
136 Mountainview Boulevard
Basking Ridge, New Jersey 07920
Phone: 212-639-5016
?
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Commack, New York 11725
Phone: 212-639-5016
?
mi
from
Commack, NY
Click here to add this to my saved trials
500 Westchester Avenue
Harrison, New York 10604
Phone: 212-639-5016
?
mi
from
Harrison, NY
Click here to add this to my saved trials
Middletown, New Jersey 07748
Phone: 212-639-5016
?
mi
from
Middletown, NJ
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Dennis Chi, MD
Phone: 212-639-5016
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Rockville Centre, New York 11570
Phone: 212-639-5016
?
mi
from
Rockville Centre, NY
Click here to add this to my saved trials